FRANKLIN LAKES, N.J., March 18, 2011 /PRNewswire/ — BD (Becton,
Dickinson and Company) (NYSE:
BDX), a leading global technology company, today announced the
completion of its acquisition of Accuri Cytometers, Inc., an Ann
Arbor, Michigan-based company that develops and manufactures
personal flow cytometers for researchers.
The acquisition expands BD’s presence into the emerging
affordable personal flow cytometer space, and helps expand the use
of flow cytometry technology by researchers in regions of the world
where ease of use and affordability are critical.
“The acquisition of Accuri Cytometers complements and broadens
BD’s offerings for life scientists by making flow cytometry more
accessible to a wider audience of scientists and clinicians,” said
William Rhodes, President, BD Biosciences. “This includes
researchers in scientific disciplines that have not traditionally
used flow cytometry, such as environmental sciences, microbiology
and marine biology.”
The financial impact of the acquisition on fiscal year 2011
earnings has been incorporated into the guidance BD provided during
its earnings call on February 8, 2011.
About BDBD is a leading global medical technology company
that develops, manufactures and sells medical devices, instrument
systems and reagents. The Company is dedicated to improving
people’s health throughout the world. BD is focused on
improving drug delivery, enhancing the quality and speed of
diagnosing infectious diseases and cancers, and advancing research,
discovery and production of new drugs and vaccines. BD’s
capabilities are instrumental in combating many of the world’s most
pressing diseases. Founded in 1897 and headquartered in Franklin
Lakes, New Jersey, BD employs approximately 29,000 associates in
more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, c
‘/>”/>
